Efficacy of stereotactic body radiation therapy with γ-knife combined with hyperthermia and targeted drug sorafenib for the treatment of recurrent and metastatic hepatocellular carcinoma
10.3969/j.issn.1000-8179.20131444
- VernacularTitle:立体定向放疗联合热疗及索拉非尼治疗复发及转移性肝癌的疗效分析
- Author:
Jingbo KANG
;
Xiangfei ZHAO
;
Qing NIE
;
Liping ZHANG
;
Qi ZHU
;
Qiliang LI
;
Renqiu WANG
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
stereotactic body radiation therapy;
hyperthermia;
sorafenib
- From:
Chinese Journal of Clinical Oncology
2013;(20):1236-1239
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of stereotactic body radiation therapy with gamma-knife (γ-SBRT) combined with targeted drug sorafenib and hyperthermia for the treatment of recurrent and metastatic hepatocellular carcinoma. Methods:A total of 71 patients with recurrent and metastatic hepatocellular carcinoma were admitted from August 2007 to December 2009. Among these patients, 39 were treated with γ-SBRT and hyperthermia (group 1); 19 were treated with γ-SBRT combined with sorafenib and hyperthermia (group 2). Results: The total efficacy rate after a three-month treatment was 83.1% (59/71). In group 1, the following results were obtained:one-and three-year local control rates of 41.0%(16/39) and 18%(7/39), respectively;one-and three-year overall survival (OS) rates of 41.2% and 17.9%, respectively; and one- and three-year progression-free survival (PFS) rates of 38.4% and 15.4%, respectively. In group 2, the following results were obtained:one-and three-year local rates of 56.3%(18/32) and 28.1%(9/32), respectively;one-and three-year OS rates of 62.5%and 28.1%, respectively;and one-and three-year PFS rates of 59.4%and 25.0%, respectively. Significant differences in OS and PFS were observed between the two groups. Conclusion:The combination ofγ-SBRT with targeted drug sorafenib and hyperthermia can be used effectively to treat recurrent and metastatic hepatocellular carcinoma. Adverse reactions are mild, and patients can tolerate this treatment.
